Bora Biologics has partnered with InvaGen Pharmaceuticals, a subsidiary of Cipla Group, to manufacture NYPOZI(TM) at its San Diego facility. This partnership marks a significant milestone in the production of NYPOZI(TM), a crucial medication for patients in need. Bora Biologics’ state-of-the-art facility in San Diego will be utilized to manufacture the drug, leveraging the company’s expertise in biologics manufacturing.
InvaGen Pharmaceuticals, as a Cipla Group company, brings extensive experience in pharmaceutical development and commercialization to the table. The collaboration between Bora Biologics and InvaGen Pharmaceuticals aims to ensure a stable and efficient supply chain for NYPOZI(TM), meeting the growing demand for this essential medication.
Under the terms of the partnership, Bora Biologics will be responsible for the manufacturing of NYPOZI(TM) at its San Diego facility, while InvaGen Pharmaceuticals will handle the regulatory and commercial aspects of the product. This strategic partnership will enable both companies to pool their resources and expertise, ultimately benefiting patients who rely on NYPOZI(TM) for their treatment.
The San Diego facility, where NYPOZI(TM) will be manufactured, is equipped with cutting-edge technology and staffed by experienced professionals. Bora Biologics’ commitment to quality and adherence to regulatory standards will ensure that NYPOZI(TM) is produced with the highest level of excellence.
This collaboration is a testament to the growing trend of partnerships in the pharmaceutical industry, where companies are coming together to leverage their strengths and expertise to bring essential medications to market. The partnership between Bora Biologics and InvaGen Pharmaceuticals is expected to have a positive impact on patients, healthcare providers, and the pharmaceutical industry as a whole.
With the manufacturing of NYPOZI(TM) at Bora Biologics’ San Diego facility underway, patients can expect a steady supply of this vital medication. The partnership between Bora Biologics and InvaGen Pharmaceuticals demonstrates the companies’ dedication to improving patient outcomes and advancing the field of biologics manufacturing. As the demand for NYPOZI(TM) continues to grow, this collaboration will play a critical role in ensuring that patients have access to the medication they need.